Mystic Ventures is a venture capital firm established in 2021 and located in Los Angeles, California. The firm focuses on investing in the burgeoning fields of psychedelic medicine and research, driven by a belief in the therapeutic potential of psychedelics for mental health and human well-being. Mystic Ventures aims to support pre-seed and seed-stage startups that are developing innovative psychedelic treatments and experiences. By leveraging a vast network and expertise across various sectors, including academia and medicine, the firm is positioned to access a growing array of opportunities within this rapidly evolving market. The firm recognizes the significant potential for growth in the psychedelic industry, which has gained traction in recent years due to increased interest and support from diverse stakeholders. Mystic Ventures prioritizes collaboration with dynamic founders and industry experts to validate investment theses and foster the success of its portfolio companies.
Psylo is a drug development company that specializes in next-generation psychedelics aimed at treating mental illness. The company focuses on creating novel therapeutics for psychiatric and neurological disorders, emphasizing non-hallucinogenic and rapid-acting agents. By leveraging psychedelic molecules, Psylo seeks to develop improved medications that provide effective alternatives to existing selective serotonin reuptake inhibitors (SSRIs). Its mission is to enhance treatment options for mood disorders, addiction, and certain neurological conditions, thereby broadening the scope of mental health care.
Spiritus Bioscience
Venture Round in 2023
Spiritus Bioscience is a drug development company seeking to apply their proprietary drug-delivery technology to the Medicalized-Psilocybin market in Oregon
Awakn Life Sciences
Post in 2023
Awakn Life Sciences is a clinical-stage biotechnology company dedicated to developing and delivering innovative psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company comprises a multidisciplinary team of chemists, scientists, psychiatrists, and psychologists who are working to create the next generation of psychedelic drugs and therapies, as well as the technologies that enable their use. Recognizing the inadequacies of current treatment options for AUD, Awakn aims to provide breakthrough therapeutics for individuals suffering from addiction, addressing a significant medical need both in the United States and internationally.
2A Biosciences
Seed Round in 2023
2A Biosciences is a pharmaceutical company founded in 2022 and based in California, USA. The company specializes in developing small molecule drugs aimed at treating inflammatory diseases through the use of 2A agonists, which target the serotonin system. Currently operating in stealth mode, 2A Biosciences is focused on advancing its innovative therapies to address unmet medical needs in the field of inflammation.
Sama Therapeutics
Pre Seed Round in 2023
Sama Therapeutics is a developer of precision neuropsychiatry solutions that leverages artificial intelligence and machine learning to enhance the efficacy of clinical trials in the field of neuropsychiatry. The company focuses on preventing clinical trial failures and reducing associated costs by effectively profiling participants who are likely to respond to specific treatments. Utilizing advanced techniques such as generative AI and deep learning transformers, Sama Therapeutics processes multimodal data, including neural electroencephalogram (EEG), physiological electrocardiogram (ECG), multi-omics, and behavioral data. This approach enables the generation of interpretable and replicable models that synthesize and validate predictive biomarkers, ultimately aiming to improve the quality of psychiatric treatments available to clinicians.
Heading Health
Venture Round in 2023
Heading Health is a technology-enabled mental health platform dedicated to enhancing access to affordable care. The company provides personalized treatment solutions that utilize evidence-based therapeutics and advanced technologies such as transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine. By leveraging these tools, Heading Health aims to deliver effective and convenient mental health services, helping patients achieve meaningful outcomes and improved well-being.
DopaGE
Seed Round in 2023
DopaGE is a developer of an overdose prevention education platform aimed at academic institutions, focusing on teaching students how to prevent, recognize, and respond to overdoses. With overdose being a leading cause of death among Generation Z and Millennial Americans, DopaGE offers a cloud-based course that is easy for institutions to implement. The platform features virtual, gamified educational content designed by emergency medical personnel and neuroscientists, which engages students and enhances their understanding of overdose response. By equipping students with life-saving knowledge and skills, DopaGE aims to make a significant impact on public health and safety in educational settings.
Journey Clinical
Series A in 2023
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.
CB Therapeutics
Series A in 2023
CB Therapeutics is a biotechnology company focused on the biosynthetic production of cannabinoids and tryptamines from sugar, utilizing a cellular agriculture platform. By employing yeast instead of traditional plant sources, the company produces pure cannabinoids, including CBD and THC, as well as psychedelic compounds and their analogs. This innovative approach aims to support clinical research for a range of serious health conditions, particularly in mental health, while promoting advancements in treatment options. CB Therapeutics seeks to enhance the healthcare industry’s capacity to address various diseases and improve overall healthspan.
Nucleus
Seed Round in 2023
Nucleus is a venture studio focused on supporting emerging companies in the psychedelic ecosystem. It provides a range of services that facilitate connections within the psychedelics industry, including therapy, education, and access to a community of investors. By incubating these companies, Nucleus aims to advance alternative medicines and promote mental health solutions, helping them establish strong brands and contribute to the growing community dedicated to the responsible use of psychedelic therapies.
Enthea
Seed Round in 2022
Enthea is a company that facilitates access to safe and affordable psychedelic-assisted therapy as a workplace benefit. It enables businesses to offer coverage for essential mental health treatments through tailored workplace benefit plans. The company has established a trusted network of certified providers specializing in Ketamine-Assisted Therapy and other forms of Psychedelic-Assisted Therapy. By creating benefit plans for early adopter employers, Enthea aims to expedite health plan coverage for these therapies, promote the adoption of industry standards, and streamline reimbursement processes. This approach allows consumers to gain access to innovative mental health care options.
Spiritus Bioscience
Seed Round in 2022
Spiritus Bioscience is a drug development company seeking to apply their proprietary drug-delivery technology to the Medicalized-Psilocybin market in Oregon
Psilera
Funding Round in 2022
Psilera is a biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases and mental health disorders. The company focuses on creating a new class of neurological medicines, with its lead asset, PSIL-006, being a non-hallucinogenic psilocybin derivative aimed at treating frontotemporal dementia (FTD). Psilera's approach involves repurposing psychoactive natural products to develop next-generation therapies that enhance cognitive function and address mood and substance use disorders. Committed to scientific excellence, Psilera aims to transform the lives of individuals affected by these challenging conditions through its pioneering research and development efforts.
Beckley Retreats
Seed Round in 2022
Beckley Retreats specializes in virtual integration programs aimed at healing individuals with neurological and psychiatric disorders. The company provides a week-long program that combines scientific insights with the therapeutic benefits of psychedelic retreats. In addition to facilitating safe and legal psychedelic ceremonies, Beckley Retreats offers training and certification for practitioners, ensuring they are equipped to deliver dedicated care. The organization emphasizes a holistic approach to healing, offering a supportive environment along with access to medical care for participants.
Maya Health
Seed Round in 2022
Naitur.ai is a company focused on enhancing psychedelic healthcare through a specialized practice management platform. Founded in 2019 and based in Denver, Colorado, the platform allows practitioners to track, manage, and measure health outcomes effectively. It offers personalized protocols and psychedelic-specific assessments that help in monitoring dosages, wellness outcomes, and psychological metrics. By streamlining these processes, Naitur.ai aims to reduce the workload for psychedelic practitioners, enabling them to serve a larger number of clients and improve mental health and well-being in the communities they support.
CB Therapeutics
Venture Round in 2022
CB Therapeutics is a biotechnology company focused on the biosynthetic production of cannabinoids and tryptamines from sugar, utilizing a cellular agriculture platform. By employing yeast instead of traditional plant sources, the company produces pure cannabinoids, including CBD and THC, as well as psychedelic compounds and their analogs. This innovative approach aims to support clinical research for a range of serious health conditions, particularly in mental health, while promoting advancements in treatment options. CB Therapeutics seeks to enhance the healthcare industry’s capacity to address various diseases and improve overall healthspan.
Sempera Organics
Seed Round in 2022
Sempera Organics operates a vertically integrated, zero-waste lab farm focused on producing high-quality certified organic mushroom ingredients. The company specializes in a variety of products, including pure mushroom powders, proprietary blends, and extracts, which are available in bulk quantities. Sempera Organics emphasizes environmentally friendly cultivation methods, ensuring a reliable and sustainable approach to mushroom production. Its offerings cater to the functional foods, nutraceuticals, and cosmeceuticals industries, providing clinically validated mushroom ingredients that can be used in both wet and dry applications. The streamlined purchasing process enhances accessibility for consumers, aligning with the company's commitment to quality and sustainability.
Freedom Biosciences
Seed Round in 2022
Freedom Biosciences is a biotechnology platform focused on developing next-generation psychedelic therapeutics. The company aims to create innovative psychedelic pharmaceuticals by utilizing the established pharmacology of ketamine and other psychedelic compounds. This approach is intended to equip medical professionals with effective treatment options for patients suffering from resistant depression and various mental disorders.
Journey Clinical
Series A in 2022
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.
Heading Health
Seed Round in 2022
Heading Health is a technology-enabled mental health platform dedicated to enhancing access to affordable care. The company provides personalized treatment solutions that utilize evidence-based therapeutics and advanced technologies such as transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine. By leveraging these tools, Heading Health aims to deliver effective and convenient mental health services, helping patients achieve meaningful outcomes and improved well-being.
Stillmind Therapeutics
Pre Seed Round in 2022
Developer of an AI-enabled healthcare technology designed for precision medicines. The company's technology employs AI, automation, and biology-first principles to develop medicines by targeting molecular patient subtypes, beginning with bipolar disorder, enabling the healthcare industry to improve patient care affected by brain disorders.
Multiverse
Seed Round in 2022
Multiverse is a digital marketplace that specializes in functional mushrooms, offering a variety of products including superfoods, snacks, supplements, and accessories. The company aims to promote the use of these mushrooms as health-enhancing items while fostering collaboration within the psychedelics industry. Through its innovative approach, Multiverse seeks to make functional mushrooms appealing to a broader audience, positioning itself as a leader in this emerging market. In addition to its core offerings, Multiverse also features SuperMush, which focuses on health supplements and streetwear inspired by the benefits of functional mushrooms.
Heading Health
Series A in 2022
Heading Health is a technology-enabled mental health platform dedicated to enhancing access to affordable care. The company provides personalized treatment solutions that utilize evidence-based therapeutics and advanced technologies such as transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine. By leveraging these tools, Heading Health aims to deliver effective and convenient mental health services, helping patients achieve meaningful outcomes and improved well-being.
Adamo Bioscience
Seed Round in 2022
Adamo Bioscience focuses on developing innovative pharmaceutical treatments, particularly for Hypoactive Sexual Desire Disorder (HSDD). The company is engaged in researching psychedelic compounds and technology solutions, aiming to create products and services that enhance love and improve interpersonal relationships. By addressing issues related to sexual trauma, Adamo Bioscience seeks to empower clients to strengthen their connections and promote healing in their relationships.
Psychedelic Water
Series A in 2022
Psychedelic Water is a pioneering brand in the legal psychedelic beverage market, focusing on creating non-alcoholic drinks designed to enhance mood and promote relaxation. The company offers a unique blend of ingredients, including kava root, damiana leaf, and green tea leaf extract, which together provide an uplifting experience without the drawbacks of traditional alcoholic beverages. These drinks aim to deliver a euphoric and clear-headed state, making them suitable for both recreational and professional settings. By championing the benefits of psychedelics, Psychedelic Water seeks to change perceptions and encourage the responsible enjoyment of their products.
Multidisciplinary Association for Psychedelic Studies
Funding Round in 2022
MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. The organization is focused on developing psychedelics and marijuana into prescription medicines, training therapists and working to establish a network of treatment centers, supporting scientific research into spirituality, creativity, and neuroscience, and educating the public honestly about the risks and benefits of psychedelics and marijuana. MAPS was founded in 1986 by Rick Doblin and is headquartered in Santa Cruz, California.
Entheo Digital
Seed Round in 2022
Driving Innovation at the Intersection of VR, Data, and Mental Health
Breathwrk
Funding Round in 2022
Breathwrk, Inc. is a company that develops a mobile application focused on guided breathing exercises aimed at enhancing mental and physical wellness. Founded in 2019 and based in Venice, California, the Breathwrk app provides users with science-backed techniques designed to alleviate anxiety, improve sleep quality, increase energy levels, and enhance athletic performance. The application offers easy-to-follow breathing exercises that help manage stress, reduce blood pressure, and improve overall mood and focus. By promoting breath work, Breathwrk seeks to address a variety of issues, including sleep disorders, low energy, and racing thoughts, making it a valuable resource for users looking to improve their well-being.
Lykos Therapeutics
Funding Round in 2022
Lykos Therapeutics aims to transform the approach to mental health by developing innovative medicines and therapeutic methods to address mental health disorders. With over thirty years of experience in researching psychedelic-assisted therapies, the company focuses on the integration of these treatments into the healthcare system. Lykos Therapeutics is dedicated to rigorous scientific standards, working to create and deliver new treatment options that facilitate healing and personal growth for individuals facing mental health challenges.
FireflyVr
Seed Round in 2022
FireflyVR is a developer of virtual reality software focused on enhancing physical health, mental well-being, education, and research through innovative digital experiences. The company aims to address the growing mental health crisis, particularly exacerbated by the COVID pandemic, by blending technology with therapeutic practices. Their flagship product, The Sanctuary, is a virtual reality experience designed to prepare patients for ketamine treatments. This clinically developed solution employs cognitive behavioral therapy techniques to alleviate pre-procedure anxiety and foster positive intentions, thereby improving treatment outcomes. The Sanctuary is designed with modularity in mind, allowing for adaptations as new dissociative medicines are approved. FireflyVR collaborates with experts in the healthcare industry to validate its offerings, with an initial focus on treating treatment-resistant depression while paving the way for broader applications in mental health therapy.
Wake Network
Series A in 2021
Wake Network, Inc. is a Toronto-based company that specializes in clinical research and the use of fungi and plant-based medicine to promote healing benefits for the mind and body. Established in June 2018, the company has developed a gold-standard regenerative feedback loop that enables it to conduct research and monitor clinical studies on an individualized basis. By integrating the expertise of wellness professionals and leveraging technology, Wake Network aims to advance the future of mental and holistic health through innovative therapeutic solutions.
HOLOS
Seed Round in 2021
HOLOS is a boutique wellness center that specializes in immersive body and mind programming, emphasizing plant medicine experiences. The center focuses on consciousness expansion and healthy living, offering retreats designed to facilitate transformation and healing. Drawing on modern neuroscience and indigenous wisdom, HOLOS provides an environment that supports guests in their personal growth journeys. Through its unique approach, the company aims to establish a new standard in wellness, integrating various practices to enhance overall well-being.
Psychedelic Water
Series A in 2021
Psychedelic Water is a pioneering brand in the legal psychedelic beverage market, focusing on creating non-alcoholic drinks designed to enhance mood and promote relaxation. The company offers a unique blend of ingredients, including kava root, damiana leaf, and green tea leaf extract, which together provide an uplifting experience without the drawbacks of traditional alcoholic beverages. These drinks aim to deliver a euphoric and clear-headed state, making them suitable for both recreational and professional settings. By championing the benefits of psychedelics, Psychedelic Water seeks to change perceptions and encourage the responsible enjoyment of their products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.